fda compounding tirzepatide sets deadlines as shortage ends FDA ban on compounded tirzepatide:

investigators want to understand what the peptide does to their methods, not just what their methods say about the peptide," said Samuel Yanner, Director of Scientific Operations at Umbrella Labs

[Abstract]2024 Feb 12;33(11):2585-2596

Woman shares what happened after she stopped taking semaglutide For Meredith Schorr, a registered nurse, working in the medical field during the coronavirus pandemic, took both a mental and physical toll

Key points: Gastrointestinal side effects became more common as the dose rose in STEP UP, from 42.8% on placebo to 61.2% on 2.4 mg and 70.8% on 7.2 mg Altered skin sensations, such as tingling, were also more common on 7.2 mg (22.9%) than on 2.4 mg (6.0%) Nausea, diarrhoea, vomiting, and constipation are the most common side effects Side effects are usually worst just after a dose increase and often settle within a few weeks Its worth considering whether increasing the dose is worth the risk of increased side effects